E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Acute urinary tract infections. |
|
E.1.1.1 | Medical condition in easily understood language |
Acute urinary tract infections |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000698 |
E.1.2 | Term | Acute cystitis |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate whether Uva ursi compared to placebo or the advice to take ibuprofen compared to no advice provide relief from urinary symptoms in adult women with suspected UTI. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate whether Uva ursi compared to placebo or the advice to take ibuprofen compared to no advice result in reduced antibiotic use in adult women with suspected UTI.
To determine the patient/practitioner barriers to implementation of a delayed antibiotic prescription approach and the use of herbal medication. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Adult women (18-70) presenting to primary care with suspected lower urinary tract infection i.e. with at least one of dysuria, urgency or frequency. • Patient able to provide informed written consent. • Women willing to accept a delayed prescription for antibiotics.
|
|
E.4 | Principal exclusion criteria |
• Known or suspected pregnancy or breast feeding In women of child bearing age a urine pregnancy test will usually be performed unless not indicated (for instance prior hysterectomy) • Known immunodeficiency state, long term corticosteroids therapy or chemotherapy • Diabetes • Has any of the following (A – F) known contra-indications or cautions to Ibuprofen and any as listed in the current SmPC: A. Asthmatics sensitive to NSAIDS/ Ibuprofen or Aspirin B. Severe heart failure and uncontrolled hypertension C. Active gastro-intestinal ulceration or bleeding D. Crohn’s disease or ulcerative colitis E. Documented poor renal function F. Chronic Kidney disease (Grade 3 - 5) • Currently or within 7 days taken antibiotics • Using a NSAID or Uva Ursi preparation and unwilling to discontinue for the study period • Suspected upper urinary tract infection (back pain, high fever>38C, systemic illness) • Women whom immediate antibiotics are otherwise indicated - frequent recurrent infection: >3 UTI episodes in past 12 months • Defect of the blood clotting system • Bladder surgery including cystoscopy in the last four weeks. • Currently taking Warfarin • Recruited to another interventional randomised control trial in previous 4 weeks.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Symptom severity at day 2-4 recorded in a validated self report diary. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Use of antibiotics. Duration of moderately bad symptoms. Reconsultation in one and three months with UTI. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 60 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Patients notes review will be completed 3 months after the last patient is randomised into the trial to assess how many return visits have been made to the GP with Urinary Tract Infections. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |
E.8.9.2 | In all countries concerned by the trial days | 29 |